Tadalafil
Product Images NDC 50436-0370

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 50436-0370). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Services, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl504360370)

Tadalafil 5 mg 30 tablet carton label by Unit Dose Services. The label includes dosing instructions, warnings to keep out of reach of children, and mandatory dosage information. The label displays the NDC 50436-0370-1 with manufacturing details from Intas Pharm Limited, India, and lot and expiration date placeholders.*

FDA Label Image

Figure (Tadalafil Figure1)

A set of four line graphs showing the difference in blood pressure (BP) readings between tadalafil and placebo over 96 hours. The graphs depict standing systolic BP, standing diastolic BP, supine systolic BP, and supine diastolic BP, with time in hours on the x-axis and the difference in mmHg on the y-axis. Each graph includes error bars indicating variability.*

FDA Label Image

Figure (Tadalafil Figure2)

A two-panel line graph comparing the effects of Tadalafil 20 mg combined with doxazosin 8 mg versus placebo with doxazosin 8 mg on systolic blood pressure over 24 hours. The top panel shows standing systolic blood pressure changes, and the bottom shows supine systolic blood pressure changes, both plotted against time post-dose in hours.*

FDA Label Image

Figure (Tadalafil Figure3)

A line graph depicting systolic blood pressure (mmHg) changes over time (0 to 12 hours) after administration of tadalafil or placebo, both with doxazosin. The graph compares four groups: 20 mg tadalafil at 08:00 with 8 mg doxazosin, placebo at 08:00 with 8 mg doxazosin, 20 mg tadalafil at 20:00 with 8 mg doxazosin, and placebo at 20:00 with 8 mg doxazosin, showing variation in systolic BP over the 12-hour period.*

FDA Label Image

Figure (Tadalafil Figure4)

A plasma tadalafil concentration-time graph showing three curves: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose after 5 days. The y-axis represents plasma tadalafil concentration in µg/L, and the x-axis shows time in hours, highlighting concentration changes over 120 hours.*

FDA Label Image

Figure 5 (Tadalafil Figure5)

A line graph showing the change from baseline in IPSS total score over a 12-week treatment duration comparing tadalafil 5 mg and placebo. The graph plots weeks on the x-axis and score change on the y-axis, with tadalafil 5 mg showing a greater decline in score compared to placebo, with statistical significance indicated at week 12.*

FDA Label Image

Figure 6 (Tadalafil Figure6)

A line graph comparing change from baseline in IPSS total score over 12 weeks of treatment between tadalafil 5 mg and placebo. The graph shows greater reduction in IPSS score with tadalafil over time, with statistically significant differences indicated at certain weeks.*

FDA Label Image

Figure 7 (Tadalafil Figure7)

A line graph showing the least-squares mean change from baseline over weeks of therapy (0, 4, 12, 26) comparing Tadalafil/Finasteride and Placebo/Finasteride treatments. The graph indicates values decreasing over time with statistical significance markers (a p<0.001, b p<0.05) at weeks 4, 12, and 26.*

FDA Label Image

Figure 8 (Tadalafil Figure8)

A line graph showing change from baseline in IPSS Total Score over a 12-week treatment duration. Two lines compare tadalafil 5 mg and placebo, with the tadalafil line showing a greater decrease in score across weeks 2, 4, 8, and 12. Statistical significance is indicated for some points.*

FDA Label Image

Chemical Structure (Tadalafil Structure)

Chemical structure of Tadalafil showing its molecular bonds and ring formations as a black line diagram on a white background.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.